Kala sends up ‘flare’ in DED; phase III positive, brisk Stride to NDA re-try March 9, 2020 By Randy Osborne No Comments Kala Pharmaceuticals Inc. plans to use its positive phase III data in dry eye disease (DED) with KPI-121 (loteprednol etabonate ophthalmic suspension 0.25%) as the basis for the resubmission of its NDA in the second quarter of 2020. Read More